Application ATN-161 has been used as an inhibitor of integrin α:5β:1 and α:vβ:3 in cultured platelet endothelial cell adhesion molecule (PECAM1)-positive endothelial cells isolated from AL (CECAL). Biochem/physiol Actions
Application ATN-161 has been used as an inhibitor of integrin α:5β:1 and α:vβ:3 in cultured platelet endothelial cell adhesion molecule (PECAM1)-positive endothelial cells isolated from AL (CECAL). Biochem/physiol Actions
Application ATN-161 has been used as an inhibitor of integrin α:5β:1 and α:vβ:3 in cultured platelet endothelial cell adhesion molecule (PECAM1)-positive endothelial cells isolated from AL (CECAL). Biochem/physiol Actions
Application ATN-161 has been used as an inhibitor of integrin α:5β:1 and α:vβ:3 in cultured platelet endothelial cell adhesion molecule (PECAM1)-positive endothelial cells isolated from AL (CECAL). Biochem/physiol Actions
Biochem/physiol Actions FIT-039 is a potent and selective cyclin-dependent kinase 9 (CDK9) inhibitor that binds to the ATP -binding pocket of CDK9 and inhibits the kinase activity of P-TEFb complex. FIT-039 inhibits replication of herpes simplex
Biochem/physiol Actions FIT-039 is a potent and selective cyclin-dependent kinase 9 (CDK9) inhibitor that binds to the ATP -binding pocket of CDK9 and inhibits the kinase activity of P-TEFb complex. FIT-039 inhibits replication of herpes simplex
Biochem/physiol Actions FIT-039 is a potent and selective cyclin-dependent kinase 9 (CDK9) inhibitor that binds to the ATP -binding pocket of CDK9 and inhibits the kinase activity of P-TEFb complex. FIT-039 inhibits replication of herpes simplex
Biochem/physiol Actions FIT-039 is a potent and selective cyclin-dependent kinase 9 (CDK9) inhibitor that binds to the ATP -binding pocket of CDK9 and inhibits the kinase activity of P-TEFb complex. FIT-039 inhibits replication of herpes simplex